JP7261793B2 - Ｓｒｐｋ１阻害剤 - Google Patents

Ｓｒｐｋ１阻害剤 Download PDF

Info

Publication number
JP7261793B2
JP7261793B2 JP2020517549A JP2020517549A JP7261793B2 JP 7261793 B2 JP7261793 B2 JP 7261793B2 JP 2020517549 A JP2020517549 A JP 2020517549A JP 2020517549 A JP2020517549 A JP 2020517549A JP 7261793 B2 JP7261793 B2 JP 7261793B2
Authority
JP
Japan
Prior art keywords
methyl
phenyl
compound
furan
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535172A (ja
JP2020535172A5 (https=
Inventor
ダグラス バクスター，アンドリュー
モリス，ジョナサン
デヴィット モーリー，アンドリュー
Original Assignee
エクソネイト リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1715637.3A external-priority patent/GB201715637D0/en
Priority claimed from GBGB1810765.6A external-priority patent/GB201810765D0/en
Application filed by エクソネイト リミテッド filed Critical エクソネイト リミテッド
Publication of JP2020535172A publication Critical patent/JP2020535172A/ja
Publication of JP2020535172A5 publication Critical patent/JP2020535172A5/ja
Application granted granted Critical
Publication of JP7261793B2 publication Critical patent/JP7261793B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020517549A 2017-09-27 2018-09-26 Ｓｒｐｋ１阻害剤 Active JP7261793B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1715637.3A GB201715637D0 (en) 2017-09-27 2017-09-27 SRPK1 Inhibitors
GB1715637.3 2017-09-27
GB1810765.6 2018-06-29
GBGB1810765.6A GB201810765D0 (en) 2018-06-29 2018-06-29 SRPK1 inhibitors
PCT/GB2018/052735 WO2019063996A1 (en) 2017-09-27 2018-09-26 INHIBITORS OF SRPK1

Publications (3)

Publication Number Publication Date
JP2020535172A JP2020535172A (ja) 2020-12-03
JP2020535172A5 JP2020535172A5 (https=) 2021-11-04
JP7261793B2 true JP7261793B2 (ja) 2023-04-20

Family

ID=63722692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020517549A Active JP7261793B2 (ja) 2017-09-27 2018-09-26 Ｓｒｐｋ１阻害剤

Country Status (7)

Country Link
US (2) US11420969B2 (https=)
EP (1) EP3687990A1 (https=)
JP (1) JP7261793B2 (https=)
CN (1) CN111448193B (https=)
AU (1) AU2018341084B2 (https=)
CA (1) CA3077749A1 (https=)
WO (1) WO2019063996A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3821947A1 (en) * 2019-11-13 2021-05-19 Libra Therapeutics, Inc. Heterocyclic trpml1 agonists
GB202010829D0 (en) 2020-07-14 2020-08-26 Exonate Ltd Compounds for treatment of neovascular diseases
EP4646263A1 (en) * 2023-01-20 2025-11-12 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Sprk1 inhibitors and methods of use
WO2025243082A2 (en) * 2024-05-24 2025-11-27 The Chinese University Of Hong Kong Covalent protein-protein interaction inhibitor against srpks

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504270A (ja) 2012-10-17 2016-02-12 ザ ユニバーシティ オブ ブリストル 眼血管形成（ｏｃｕｌａｒｎｅｏｖａｓｃｕｌａｎ）を治療するのに有用な化合物
WO2017064512A1 (en) 2015-10-16 2017-04-20 Exonate Limited Compounds
JP2017518360A (ja) 2014-04-17 2017-07-06 ザ ユニバーシティ オブ ノッティンガム 化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820178B2 (en) 2001-08-01 2010-10-26 University of Brisol VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
US7429603B2 (en) * 2003-04-25 2008-09-30 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
CA2801848C (en) * 2003-12-26 2015-03-31 Masatoshi Hagiwara Methods for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
US20140249135A1 (en) 2007-03-01 2014-09-04 Novartis Ag Pim kinase inhibitors and methods of their use
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments
WO2009020198A1 (ja) 2007-08-03 2009-02-12 Kinopharma, Inc. 抗ｄｎａウイルス作用を有するアニリン誘導体
GB0803912D0 (en) 2008-02-29 2008-05-07 Univ Bristol Novel Uses of VEGFxxxb
JP2012509306A (ja) 2008-11-22 2012-04-19 ザ ユニバーシティ オブ ブリストル ＶＥＧＦｘｘｘｂの新規な使用
WO2011036429A1 (en) 2009-09-25 2011-03-31 The University Of Bristol Detection of risk of pre-eclampsia
GB201009173D0 (en) 2010-05-28 2010-07-14 Univ Bristol Treatment of pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504270A (ja) 2012-10-17 2016-02-12 ザ ユニバーシティ オブ ブリストル 眼血管形成（ｏｃｕｌａｒｎｅｏｖａｓｃｕｌａｎ）を治療するのに有用な化合物
JP2017518360A (ja) 2014-04-17 2017-07-06 ザ ユニバーシティ オブ ノッティンガム 化合物
WO2017064512A1 (en) 2015-10-16 2017-04-20 Exonate Limited Compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BATSON J. et al.，Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease，ACS chemical biology，2017年03月17日，Vol.12, No.3，p.825-832
REGISTRY（STN）[online]，2015年05月15日，[検索日 2022.08.05]，CAS Registry Number: 1705453-84-4

Also Published As

Publication number Publication date
JP2020535172A (ja) 2020-12-03
CA3077749A1 (en) 2019-04-04
US12325704B2 (en) 2025-06-10
CN111448193A (zh) 2020-07-24
AU2018341084A1 (en) 2020-04-23
WO2019063996A1 (en) 2019-04-04
US20200270249A1 (en) 2020-08-27
CN111448193B (zh) 2023-12-22
EP3687990A1 (en) 2020-08-05
US20220389015A1 (en) 2022-12-08
US11420969B2 (en) 2022-08-23
AU2018341084B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
US12325704B2 (en) SRPK1 inhibitors
JP6579714B2 (ja) 化合物
JP6866381B2 (ja) 化合物
CA3017972A1 (en) Compounds and methods for kinase modulation and indications therefore
JP6738512B2 (ja) 眼血管形成（ｏｃｕｌａｒ ｎｅｏｖａｓｃｕｌａｎ）を治療するのに有用な化合物
CA3047580A1 (en) Compounds and methods for cdk8 modulation and indications therefor

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210924

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230410

R150 Certificate of patent or registration of utility model

Ref document number: 7261793

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150